Hematopoietic cells can be transformed through the acquisition of autocrine growth factor production. Because of their ability t o inhibit autocrine growth, antibodies directed against the growth factor or its receptor may have therapeutic potential. However, these agents may also inhibit normal cell development. We have developed two monoclonal antibodies, 468 and 2F2, directed against a protein of 110 t o 150 Kd that interacts with the interleukin-3 (IL-3) receptor (R) complex. These antibodies inhibit IL-)induced proliferation of nonleukemic and leukemic IL-3-dependent cell lines, as well as the autonomous growth of WEHI-3B in vitro and in vivo. These results suggest the possibility that anti-IL-3R antibodies may be useful in the treatment of some leukemias. However, the effect of anti-IL-3R antibodies on normal myeloid development in vitro has not been examined. We examined the effect of 4G8 and 2F2 on the growth in vitro of colony-forming unit granulocyte-macrophage (CFU-GM) colonies induced by IL-3, granulocyte colony-stimulating factor NTERLEUKIN-3 (IL-3) is a 28-Kd myeloid growth
I factor produced by in vitro stimulated normal cells of a limited number of lineages that include T lymphocytes, keratinocytes, mast cells, and natural killer
The production of IL-3 also has been shown in some transformed myeloid cells, raising the possibility that autocrine production of IL-3 may have contributed to their transformed
The ability of neutralizing anti-IL-3 antibody to inhibit the growth of one IL-3-producing transformed cell line supports this conclusion? Additional support for an autocrine mechanism involving IL-3 and its receptor (IL3R) in IL-3-producing transformed cells was provided by our recent studies using the monoclonal antibody (MoAb) 4G8.8 This antibody recognized a surface protein of molecular weight (Mr) 110 to 150 Kd that interacts with the IL-3R9 and inhibited the growth of the IL-3-producing myelomonocytic leukemia cell line, WEHI-3B, both in vitro and in vivo.* Most spontaneously occurring murine and human acute myeloid leukemic (AML) cells display receptors for IL-3. Many human AML cells have been shown to be responsive to exogenous IL-3 in vitro1°-12 and occasional AML samples have been shown to produce IL-3. 13 As for acute lymphocytic leukemia (ALL), low level expression of IL3R has been shown in 2 of 5 human T-ALL samples by Park et al. 1° In addition, T-ALL cells frequently have shown IL-3 production. 13 While these investigators did not examine the ability of the T-ALL samples to proliferate in response to IL-3, we have established a granulocyte-macrophage colonystimulating factor (GM-CSF)-dependent cell line, TALL-101, from a child with T-ALL that could also be maintained in IL-3,14,15 suggesting that some T-ALL cells proliferate in response to IL-3. In the instance of B-lineage ALL, in two cases with t(5;14)(q31:q32), this translocation was found to join the Ig heavy chain and IL-3 genes, resulting in activation of IL-3 gene transcription16J7; the response of the leukemic cells to IL-3 was not determined.
(G-CSF), granulocyte-macrophage CSF (GM-CSF), and macrophage-CSF (M-CSF). Our results show that while 4G8 and 2F2 inhibited CFU-GM colony formation induced by IL-3, they augmented colony formation induced by the other hematopoietins. 4G8 and 2F2 also enhanced G-CSF-induced proliferation of 32Dc13 and GM-CSF-induced proliferation of PT18, confirming that the effect on CFU-GM was a direct effect. Finally, 4G8 and 2F2 inhibited G-CSF-induced differentiation of 32Dc13, similar t o low levels of IL-3; yet, neither 4G8 nor 2F2 blocked binding of G-CSF t o its receptor. These results indicate that, in the absence of IL-3 and in the presence of other hematopoietins, 4G8 and 2F2 can function as weak IL-3 agonists. These studies suggest that antibodies such as 468 and 2F2, directed against components of the IL-3R. could potentially augment myeloid growth in vivo, rather than inhibit myeloid growth.
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Antibodies effective at blocking signal transduction through the IL-3R may be useful in the treatment of some spontaneous acute myeloid and lymphoid leukemias, similar to the use of anti-Tac antibodies in a human T-lymphotropic virus-1 (HTLV-1)-induced leukemia. However, because most normal myeloid cells express IL-3 receptors, antibodies directed against the IL-3R may have a detrimental effect on normal hematopoiesis.
To determine the impact of anti-IL3R antibodies on hematopoiesis in vitro, we examined the effect of 4G8 on murine colony-forming unit granulocyte-macrophage (CFU-GM) colonies induced by IL-3, GM-CSF, granulocyte-CSF (G-CSF), and macrophage-CSF (M-CSF). Our results show that while 4G8 inhibited IL-3-induced colony formation, it enhanced colony formation by the other hematopoietins and enhanced G-CSF-induced proliferation of 32Dc13 and GM-CSF-induced proliferation of PT18. These results, together with the ability of 4G8 and 2F2 to inhibit G-CSFinduced differentiation of 32Dc13, indicated that these antibodies can function as weak IL-3 agonists. Our findings 360 TWEARDY ET AL suggest that antibodies like 4G8 and 2F2 could potentially augment normal hematopoiesis in vivo.
MATERIALS AND METHODS
The mouse myelomonocytic leukemia cell line, WEHI-3B,18 was maintained in Iscove's modified Dulbecco's medium (IMDM) supplemented with 1% fetal calf serum (FCS), 2 mmol/L L-glutamine, penicillin (100 U/mL), streptomycin (100 p,g/mL), and 2.5% WEHI3B conditioned medium (W3CM). The 32Dc13 cell line was derived from a murine long-term bone marrow culture19 and shown to respond to G-CSF by proliferating followed by differentiation into mature neutrophilsM; this cell line was maintained and induced to differentiate with G-CSF as described? PT-18 is an IL-3-or GM-CSF-dependent cell line that was maintained as described? RAW 264.7 is a murine macrophage cell line obtained from the American Tissue Type Culture Collection (ATCC, Rockville, MD); it was maintained in RPMI-1640 supplemented with 10% FCS, 2 mmol/L L-glutamine, penicillin, and streptomycin.
Recombinant murine IL-3 was obtained from Genzyme (Boston, MA). W3CM was used as a source of IL-3 for maintenance of 32Dc13 and in some experiments. Recombinant human G-CSF was obtained from Genetics Institute (Cambridge, MA). In some experiments, partially purified native human G-CSF was used.21 Purified murine M-CSF was kindly provided by Dr Abdul Waheed. Recombinant murine GM-CSF was obtained from DNAX.
The 4G8 and 2F2 hybridomas were established as de~cribed.~ Jlj.10, a rat IgM antimouse Thyl.2 hybridoma, was purchased from ATCC. Conditioned medium from each hybridoma was prepared and partially purified as described? An IgG MoAb against the murine M-CSF receptor (anti-mMCSFR Ab) was provided as a concentrated hybridoma supernatant by Dr Abdul Waheed and used as directed?
Bone marrow cells were obtained from the femurs of 8-to 12-week-old female C57BL6 mice. Cells (l@/plate) were incubated in duplicate or triplicate in media containing 1% agarose (sea plaque) with or without hematopoietin and hybridoma supernatant. Colonies ( > 50 celldaggregate) were counted on day 7, as described. 23 Proliferation assay. Cells (lO"/microtiter well) were incubated in triplicate in media containing 10% (PT18) or 20% (32Dc13) FCS with or without hematopoietin or antibody. Wells were pulsed with 0.5 kCi of tritated thymidine 18 hours before harvesting on day 3 onto glass fiber filters. The filters were counted by liquid scintillation and the results expressed as counts per minute (CPM) incorporation.
Morphologic and cytochemical characterization of 32Dc13 was performed as described.m Briefly, cells were incubated at 0.5 X lo6 cells/mL in the presence of G-CSF (300 U/mL) with or without antibody (10 kg/mL). Cells were concentrated and stained for myeloperoxidase by the Giemsa method using kits according to the manufacturer's instructions (Sigma, St Louis, MO).
Total RNA (10 kg) was separated by formaldehyde-agarose gel electrophoresis and capillary blotted onto Zetabind nylon membranes (Cuno, Meridian, a). Membranes were hybridized with nick-translated 32P-dCTP-labeled cDNA probe and autoradiographed. A human myeloperoxidose probe (2.2-kb fragment in pUC8 spanning nearly the entire coding sequence) was obtained from Dr Keith Johnson." A rat 18s rRNA probe was obtained from Dr Christine Milcarek (University of Pittsburgh School of Medicine).
Radioligand binding studies. Escherichia coli-derived mutein hG-CSF, KW-2228, was kindly provided by Dr T. Okabe. Purified Cell lines.
CSFs.
MoAbs.
CFU-GM assay.
Morphologic and cytochemical characterization of 32Dc13.
Northern blotting. native mM-CSF was the generous gift of Dr Abdul Waheed. Each was iodinated as described.25,26 Specific activity was 7 x lo7 cpm/ kg forKW-2228 and 2 x lo7 cpmlpg for mM-CSF. Bioactivity of KW-2228 was verified by proliferation assays using 32Dc13 and was unaltered by iodination. Binding studies were performed in triplicate at 4°C in a total volume of 1 mL as described.% Cells (lo6) in 0.9 mL McCoy's medium containing 15% fetal bovine serum (FBS) were added to 0.1 mL of lBI-KW-2228 or l%mM-CSF containing 4 x lo5 CPM with or without antibody and allowed to incubate for 2 hours at 4°C. After incubation, cells were washed two times with 1 mL of medium and the pellet resuspended in 0.1 mL and counted using a gamma counter.
KW-2228 has been shown to bind human neutrophils with a kd of 250 pmol/L,z similar to the kd of the murine G-CSF receptor for murine G-CSF (180 pmol/L)J7 Binding of KW-2228 to neutrophils was maximal at 45 minutes at 4"C.= However, maximal binding of mature murine G-CSF to murine bone marrow cells at 4°C required up to 15 hoursB; saturation of receptors on murine bone marrow cells under these conditions was achieved at a Native murine M-CSF binds to murine peritoneal macrophages or macrophage cell lines with a kd of 28 pmol/L at 4°C; saturation is achieved at m~l / L .~~ For our studies, we chose a concentration of lZI-M-CSF below saturation (700 pmol/L); the concentration of the anti-mM-CSF antibody was approximately 4 X mol/L.
Unless otherwise indicated, data were compared using the Student's t-test after log transformation to stabilize error variances.
mol/L).25
Statistical analysis.
RESULTS
Effects of 4G8 and 2F2 on CFU-GM colony formation. Consistent with its effects on IL3dependent normal9 and leukemic8 cell lines, 4G8 (Fig 1) inhibited IL-3-induced CFU-GM colony formation, achieving 66% inhibition at 30 pg/mL of antibody in the presence of 30 U/mL IL-3 (P = .0299). Control antibody, Jlj.10, an IgM antibody directed against the Thy 1.2 antigen and prepared in an identical fashion, had no effect on IL-3-induced CFU-GM colony formation. Antibody 2F2 also inhibited IL-3-induced CFU-GM colony formation (Table l) , up to 83% at a concentration of 30 pg/mL.
In contrast to its effect on IL-3-induced CFU-GM colony formation and somewhat to our surprise, 4G8 augmented colony formation induced by GM-CSF (P = .0019), M-CSF (P = .Owl), and G-CSF (P = .002) by 1.3-to 2.7-fold at all concentrations tested for each hematopoietin (Fig 2) . The results of three separate experiments examining the effect of 4G8 on CFU-GM formation induced by G-CSF at 100 U/mL (Table 2) showed 77% augmentation by 4G8 at 100 pg/mL (P = .022, paired t-test).
MoAb 2F2 had a similar inhibitory effect on IL-3-induced CFU-GM formation and an identical augmenting effect on CFU-GM formation induced by the other cytokines (Table 1 ). Both the inhibitory and stimulatory effects of 4G8 and 2F2 appeared to affect granulocyte, macrophage, and mixed granulocyte/macrophage colonies equally (data not shown), suggesting that all CFU-GM were similarly susceptible to the effects of these antibodies. Effects of 4G8 and 2F2 on dual factor-dependent cell lines. To confirm that the augmenting effect of 4G8 and 2F2 is mediated through a direct effect on myeloid precursor cells and not through an accessory cell, we examined the effects of 4G8 and 2F2 on the proliferation of IL-3-dependent cell lines that also proliferate in response to another hematopoietin. Two cell lines were tested, 32Dc13 and PT18. The 32Dc13 cell line is an IL-3-dependent cell line known to proliferate and differentiate in response to G-CSF.20 PT18 proliferates in response to either IL-3 or GM-CSF.y In an earlier report,y we showed that 4G8 and 2F2 inhibited the IL-3-induced proliferation of both 32Dc13 and PT18 by up to 80% and 50%, respectively. In contrast to its effect on IL-3-induced proliferation, antibody 4GS augmented G-CSF-induced proliferation of 32Dc13 by 1.5-fold to threefold at concentrations of G-CSF of 10 to 100 U/mL (Fig 3) . Similarly, 2F2 increased G-CSF-induced proliferation by 1.5-fold to threefold at concentrations of G-CSF of 1 to 30 U/mL, whereas control antibody Jlj.10, if anything, had a slight inhibitory effect on G-CSF-induced proliferation of 32Dc13. The effects of 4G8 and 2F2 are similar to the effect of a low concentration of IL-3 (0.3 U/mL), which alone was unable to induce proliferation of 320 c13 cells (Fig 3D) .
4G8 and 2F2 each had an identical effect on PT18 (Fig 4) . Each increased GM-CSF-induced proliferation by 1 S-fold to twofold at concentrations of GM-CSF from 3 to 300 U/mL. Jlj.10 had no effect on GM-CSF-induced proliferation of PT18 cells.
Effects of 4G8 and 2F2 on G-CSF-induced differentiation of 320~13. The ability of 4G8 and 2F2 to enhance G-CSF-induced proliferation of 32Dc13 in a fashion similar to subliminal levels of IL-3 indicated that these antibodies may be weak IL-3 agonists. We had previously shown that 32Dc13 cells washed free of IL-3 and incubated with G-CSF undergo one to two cycles of proliferation followed by differentiation into neutrophils. One of the earliest events signalling G-CSF-induced differentiation was the induction of myeloperoxidase (MPO) messenger RNA (mRNA) and protein. The induction of MPO was delayed or blocked by coincubation of cells in G-CSF and IL-3.20 To further support the conclusion that these antibodies are weak IL-3 agonists, we examined the effect of 4G8 and 2F2 on the induction of MPO mRNA by G-CSF in 32Dc13 cells. 4G8, at 1 and 10 Fg/mL, and 2F2, at 10 Fg/mL, blunted the G-CSF-mediated induction of MPO mRNA similar to the effect of IL-3; control antibody Jlj.10 had no effect on the induction of MPO mRNA by G-CSF (Fig 5) . The ability of 2F2 to inhibit G-CSF-induced differentiation of 32Dc13 was also shown cytochemically (Table 3) . Antibody 2F2 (at 10 pg/mL) caused a delay in the G-CSFinduced maturation of 32Dc13 examined on days 4, 6, 9, and 12 relative to cells incubated in G-CSF alone; 2F2 also caused a reduction in the pcrcentage of cells that were MPO positive on days 9 and 12.
Antibody 4G8 was shown to inhibit binding of IL-3, IL-2, and IL-4 to their respective receptors? To dctermine if the effect of 4G8 or 2F2 on G-CSF-induced diffcrentiation was due to inhibition of G-CSF binding, we pcrformed radioligand binding studies with a biologically active mutein of G-CSF, KW-2228, that is stable aftcr iodination ( Table 4) . While 100-fold excess of unlabclcd KW-2228 (2 x lo-' mol/L) was able to block binding by 85%. neither 4G8 nor confirm that the ability of 4G8 and 2F2 to augment colonies was a direct effect on CFU-GM, we examined dual-factorresponsive cell lines, 32Dc13 (IL-3 and G-CSF) and PT18 (IL-3 and GM-CSF). Both 4G8 and 2F2 enhanced G-CSFinduced proliferation of 32Dc13 and GM-CSF-induced proliferation of PT18. Furthermore, 4G8 and 2F2, in a fashion identical to low levels of IL-3, inhibited G-CSFinduced differentiation of 32Dc13. Yet, these antibodies do not affect G-CSF binding. Each of our findings examining the effects of 4G8 and 2F2 on the actions of other hematopoietins are consistent with previously observed effects of low levels of IL-3, including the ability of IL-3 to augment CFU-GM colonies induced by GM-CSF, M-CSF, and G-CSPO to augment proliferation of dual-factordependent cell lines31 (Tweardy et al, unpublished) and to inhibit G-CSF-induced differentiation.*O Taken together, our findings suggest that, in the absence of IL-3 and in the presence of other hematopoietins, 4G8 and 2F2 can mimic low levels of IL-3 and act as weak IL-3 agonists. Recently, it has been shown that the native mIL-3R binds IL-3 with low and high affinity.32 Murine IL-3 has been shown to bind and cross-link to three cell surface proteins of 60 to 75, 90 to 125, and 140 to 170 Kd.33 These three proteins appear to be structurally related and most likely are derived from the same precursor.33 This precursor appears to be encoded by the AIC2A gene.% However, because AIC2A transfected cells bind mIL-3 only with low affinity, are not stimulated to phosphorylate tyrosinecontaining proteins, and do not internalize bound mIL-3, it is certain that the AIC2A gene encodes for only one protein of a multiple-component mIL-3R complex. Our recent in vitro findings with 4G8 and 2F29 strongly suggested that 4G8 and 2F2 recognized a second protein that is capable of interacting with the mIL-3R complex. Both 4G8 and 2F2 recognized an identical cell surface protein (4G8/2F2 antigen) of 110 to 150 Kd that is distinct from the AIC2A antigen and is expressed at moderate to high density by most myeloid and lymphoid cells, but not by mature B cells. Antibody 4G8 inhibited high-affinity binding of IL-3 and both antibodies blocked IL-3-induced proliferation, suggesting that the 4G8/2F2 antigen can interact with the mIL-3R. The results reported here showing the ability of 4G8 and 2F2 to act as weak IL-3 agonists lend strong additional support to the conclusion that the 4G8/2F2 antigen can interact with the mIL-3R and may participate in IL-3-mediated signal transduction.
In our earlier r e p~r t ,~ we suggested that these antibodies may block IL-3 signal transduction by cross-linking receptors on the cell surface in an unfavorable configuration, thereby interfering with optimal IL-3-induced receptor oligomerization. Our recent data would suggest that the antibody-mediated oligomerization of IL-3 receptors, while interfering with optimal IL-3-induced oligomerization, may permit a signal to be transduced through the IL-3R complex. This signal was below the threshold to alone cause proliferation similar to subliminal levels of IL-3; it could only be observed in the absence of IL-3 and in the presence of other hematopoietins whose effects are augmented by low levels of IL-3. Myeloid precursor and mature myeloid cells possess receptors for IL-3, GM-CSF, M-CSF, and G-CSF.3s M-CSF, G-CSF, and, possibly, GM-CSF can be detected in the serum of normal adult mice.35 GM-CSF has been isolated from the extracellular matrix of normal bone marrow stromal cells.36 In addition, M-CSF, GM-CSF, and G-CSF are constitutively produced by stromal cells in long-term bone marrow cultures.37 Thus, it is very likely that these hematopoietins contribute to hematopoietic homeostasis. The detection of IL-3 in the serum or bone marrow of normal mice, however, has not been reported, making it difficult to attribute a role for IL-3 in the maintenance of hematopoiesis. Consequently, the effect on normal hematopoiesis in vivo of antibodies like 4G8 and 2F2, directed against components of the IL-3 receptor, may not be significant. In fact, our results with the other hematopoietins suggest that antibodies of this type may augment normal hematopoiesis in vivo. Taken together with our previously published studies: these results suggest that antibodies like 4G8 and 2F2 may not only be useful in the therapy of some leukemias, but also may avoid one of the major side effects of current treatment regimens.
Using a bacteriophage (AZAPII) expression system, we have identified a candidate cDNA clone encoding the 4G8/2F2 antigen. Partial sequence shows no homology with sequences in GenBank. Isolation and characterization of the cDNA for the 4G8/2F2 antigen may have important implications for both normal and leukemic myeloid development.
